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Acute graft-versus-host disease (aGvHD) is the most frequent and serious complication 
following hematopoietic stem cell transplantation (HSCT), with a high mortality rate. 
A clearer understanding of the molecular pathogenesis may allow for improved thera-
peutic options or guide personalized prophylactic protocols. Circulating microRNAs are 
expressed in body fluids and have recently been associated with the etiology of aGvHD, 
but global expression profiling in a HSCT setting is lacking. This study profiled expression 
of n = 799 mature microRNAs in patient serum, using the NanoString platform, to identify 
microRNAs that showed altered expression at aGvHD diagnosis. Selected microRNAs 
(n =  10) were replicated in independent cohorts of serum samples taken at aGvHD 
diagnosis (n = 42) and prior to disease onset (day 14 post-HSCT, n = 47) to assess 
their prognostic potential. Sera from patients without aGvHD were used as controls. 
Differential microRNAs were investigated in  silico for predicted networks and mRNA 
targets. Expression analysis identified 61 microRNAs that were differentially expressed at 
aGvHD diagnosis. miR-146a (p = 0.03), miR-30b-5p (p = 0.007), miR-374-5p (p = 0.02), 
miR-181a (p = 0.03), miR-20a (p = 0.03), and miR-15a (p = 0.03) were significantly 
verified in an independent cohort (n = 42). miR-146a (p = 0.01), miR-20a (p = 0.03), 
miR-18 (p = 0.03), miR-19a (p = 0.03), miR-19b (p = 0.01), and miR-451 (p = 0.01) 
were differentially expressed 14 days post-HSCT in patients who later developed aGvHD 
(n = 47). High miR-19b expression was associated with improved overall survival (OS) 
(p = 0.008), whereas high miR-20a and miR-30b-5p were associated with lower rates 
of non-relapse mortality (p = 0.05 and p = 0.008) and improved OS (p = 0.016 and 
p = 0.021). Pathway analysis associated the candidate microRNAs with hematological 
and inflammatory disease. Circulating biofluid microRNAs show altered expression at 
aGvHD onset and have the capacity to act as prognostic and diagnostic biomarkers. 
Their differential expression in serum suggests a role for circulatory microRNAs in aGvHD 
pathology, which warrants further investigation.
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highlighTs
•	 Comprehensive	 profiling	 identified	 61	 microRNAs	 that	












of	 hematological	 diseases,	 including	 leukemia	 and	 lymphoma.	
However,	up	to	40%	of	HSCT	patients	will	develop	graft-versus-
host	disease	 (GvHD)	 in	 either	 an	 acute	or	 a	 chronic	 form	 (2).	
Acute	GvHD	(aGvHD)	is	a	serious	complication	of	HSCT	and	
occurs	 when	 T  cells	 in	 the	 graft	 elicit	 an	 immune	 response	







potential	 clinical	 relevance.	 These	 small	 (22–25	 nucleotides),	
non-coding	 RNAs	 regulate	 gene	 expression	 by	 binding	 to	 the	










Together,	 these	 protein	 and	 vesicle	 chaperones	 allow	 selective	
export	of	microRNAs,	protecting	them	within	the	extracellular	
environment	(6).





focusing	 on	 circulating	 protein	 biomarkers	 (11),	 microRNAs	
may	 offer	 several	 advantages	 as	 they	 are	 lower	 in	 complexity,	






or	 outcome	 (13–17),	 and	 some	 investigations	 have	 included	
profiling	of	an	extended	microRNA	repertoire	(13,	17).	However,	




Thus,	 comprehensive	 profiling	 of	 the	microRNA	expression	








conserved	 mature	 human	 microRNAs	 in	 post-HSCT	 patient	
serum	 using	 NanoString	 nCounter	 technology,	 to	 explore	 the	
spectrum	of	microRNAs	demonstrating	differential	expression	at	
aGvHD	diagnosis.	This	provides	a	sensitive,	highly	multiplexed	
method	 for	 detecting	 direct	 digital	 counts	 of	 each	microRNA,	

























aGvHD	grade	was	 diagnosed	 by	 clinicians	 in	 accordance	with	





Table 2 | clinical and outcome details of the diagnostic and prognostic cohorts.
Diagnostic cohort Prognostic cohort cohort comparison
all no gvhD, N (%) agvhD, N (%) p Value all no gvhD, N (%) agvhD, N (%) p Value p Value
All 42 18 24 47 23 24
Patient gendera
Male 27 (64) 11 (61) 16 (67) 0.75a 23 (49) 10 (43) 13 (54) 0.56a 0.20a
Female 15 (36) 7 (39) 8 (33) 24 (71) 13 (57) 11 (46)
Donor gendera
Male 32 (76) 14 (78) 18 (75) 1.0a 34 (72) 17 (74) 17 (71) 1.0a 0.81a
Female 10 (24) 4 (22) 6 (25) 13 (28) 6 (26) 7 (29)
Mean age 
(years)b
51 50 52 0.62b 49 49 49 0.98b 0.82b
Range (years) 20–65 26–61 20–65 20–69 24–68 20–69
relationshipa
MUD 36 (86) 14 (78) 22 (92) 0.38a 28 (60) 10 (43) 18 (75) 0.04a 0.02a
SIB 6 (14) 4 (22) 2 (8) 19 (40) 13 (56) 6 (25)
conditioninga
RIC 35 (83) 15 (83) 20 (83) 1.0a 20 (43) 19 (83) 16 (67) 0.32a 0.01a
Myeloablative 7 (17) 3 (17) 4 (17) 27 (57) 4 (17) 8 (33)
Outcomea
Alive 29 (69) 15 (83) 14 (58) 28 (60) 15 (65) 13 (54) 0.56a 0.38a
Dead 13 (31) 3 (17) 10 (42) 0.10a 19 (40) 8 (35) 11 (47)
Clinical details of the diagnostic (n = 42) (collected at the time of aGvHD diagnosis ±3 days) and prognostic (n = 47) (collected on day 14 post-HSCT) Newcastle cohorts to test 
for differences between aGvHD and no aGvHD groups and also between the diagnostic and prognostic cohorts. Outcome was evaluated from the date of death or the date last 
assessed in clinic.
p Values were calculated using the Fisher’s exact testa or independent two sample t-testb, as appropriate.
MUD, matched unrelated donor; SIB, sibling donor; RIC, reduced intensity conditioning; N, number; HSCT, hematopoietic stem cell transplantation; aGvHD, acute graft-versus-host 
disease.
Table 1 | clinical details of the nanostring cohort.
iD Disease 
status










Dx Tx type cond
1 aGvHD 23/06/2014 52 F CSA + MMF 57 Skin II 57 CML MUD RIC
2 aGvHD 30/07/2014 33 M CSA + MMF 62 Skin II 62 AML MUD RIC
3 aGvHD 09/05/2014 56 F CSA + MMF 26 Skin II/GI II 26 MDS MUD RIC
4 aGvHD 10/06/2014 58 M CSA + MMF 23 Skin II 23 MDS SIB RIC
5 aGvHD 17/07/2014 51 F CSA 34 Skin III 34 AML MUD MYO
6 aGvHD 14/11/2014 27 M CSA + MTX 7 Skin II 7 MDS SIB RIC
7 No aGvHD 20/01/2010 57 M CSA + MTX N/A N/A 57 AML MUD RIC
8 No aGvHD 22/03/2013 60 M CSA + MMF N/A N/A 31 AML MUD RIC
9 No aGvHD 11/04/2013 41 M CSA + MMF N/A N/A 40 ALL-T MUD RIC
10 No aGvHD 05/07/2013 51 M CSA + MTX N/A N/A 45 CML SIB MYO
11a No aGvHD 17/01/2014 47 M CSA + MTX N/A N/A 38 AML MUD MYO
12 No aGvHD 04/04/2014 43 F CSA + MTX N/A N/A 40 AML SIB RIC
A total of 12 diagnostic serum samples taken from Vienna patients at aGvHD onset (n = 6) or from aGvHD-free controls (n = 6) were analyzed for microRNA expression using 
NanoString.
Tx, transplant; Proph, prophylaxis; Dx, diagnosis; Cond, conditioning; F, female; M, male; CSA, cyclosporine A; MMF, mycophenolate mofetil; MTX, methotrexate; GI, 
gastrointestinal; CMML, chronic myelomonocytic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL-T, T-lineage acute lymphoblastic leukemia; CML, 
chronic myeloid leukemia; MUD, matched unrelated donor; SIB, sibling donor; RIC, reduced intensity conditioning; MYO, myeloablative conditioning; N/A, not applicable.
aSample removed from the final NanoString data analysis due to failed quality control parameters.
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serum rna isolation
Whole	 blood	 samples	were	 collected	 in	 7 ml	 vacutainers	 con-
taining	 no	 anticoagulant	 and	 left	 to	 clot,	 and	 the	 supernatant	
was	 centrifuged	 at	 500  g	 for	 5 min	 and	 then	 stored	 at	−80°C.	
Total	RNA	was	 isolated	 from	250 μl	aliquots	using	 the	Norgen	






and	RNA	6000	Pico	kit	 (Agilent),	 and	 interassay	variation	was	
reported	as	7.21%.	Variation	in	RNA	recovery	between	samples	




Expression	 Assay	 Kit	 (NanoString	 Technologies),	 based	 on	
miRBase	v21.	The	code	set	incorporated	799	mature	microRNAs	
4Crossland et al. Serum microRNA Expression in aGvHD
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and	included	6	positive	controls,	8	negative	controls,	6	 ligation	
controls,	 and	 5	 mRNA	 housekeeping	 controls	 (ACTB,	 B2M,	










Reverse	Transcription	kit	 (Life	Technologies),	 according	 to	 the	
supplier’s	protocol.	Each	15 μl	 reaction	 incorporated	4 μl	 total	
RNA.	 Quantitative	 RT-PCR	 was	 performed	 incorporating	
SensiFast	 Probe	Hi-Rox	 reagent	 (Bioline).	 Each	 10 μl	 reaction	
incorporated	3.25 μl	cDNA,	and	thermal	cycling	was	performed	
in	 triplicate	 using	 the	 7900HT	 Real-Time	 PCR	 System	 (Life	
Technologies),	 according	 to	 manufacturer’s	 recommended	
conditions.	The	interassay	and	intraassay	variation	were	reported	
for	 an	 example	 microRNA	 (miR-15a:	 interassay  =  1.89%,	
intraassay =  2.26%)	 for	 proof	 of	 principle	 of	 the	 quantitative	
performance	of	qRT-PCR	(Table	S1	in	Supplementary	Material).	
In	addition,	an	example	microRNA	(miR-146a)	was	assessed	in	





The	 biological	 targets	 of	 identified	 microRNAs	 were	 investi-
gated	 using	 QIAGEN’s	 Ingenuity®	 Pathway	 Analysis	 (IPA®).2	





For	 NanoString	 analysis,	 fold	 change	 (FC)	 expression	 differ-






were	 generated	 using	 a	 two-tailed	 t-test.	 Volcano	 plots	 were	
generated	using	functions	within	the	“ggplot2”	(v2.1.0)	package,	
and	 heatmaps	 were	 constructed	 using	 “gplots”	 (v2.17.0)	 and	























both	 relapse	 and	 non-relapse	mortality	 (NRM)	 (23)	 using	 “R”	
package	“cmprsk”	(competing	risks)	(24).	To	test	for	confound-




determined	 using	 Pearson’s	 correlation	with	Holm–Bonferroni	
multiple	comparisons	adjustment	applied	(25).
resUlTs
clinical Details of the cohorts
NanoString	microRNA	 expression	 profiling	was	 performed	 on	
serum	samples	 taken	 from	12	adult	 (mean	age	48 years,	 range	
27–60  years)	 allo-HSCT	 patients	 transplanted	 between	 2010	




aGvHD	 prophylaxis	 included	 cyclosporine  ±  mycophenolate	
mofetil	or	methotrexate.	Six	patients	showed	clinical	symptoms	
of	 aGvHD	at	 the	 time	of	 sample	 collection	 (skin	 II–III	 and/or	
gastrointestinal	II),	with	a	mean	time	of	onset	of	35 days	(range	
7–62 days	post-HSCT),	while	six	were	aGvHD	free	(Table 1).
Verification	 of	 NanoString	 results	 was	 performed	 using	
a	 diagnostic	 cohort	 (n  =  42)	 of	 serum	 samples	 taken	 from	
patients	at	the	onset	of	aGvHD	symptoms	(mean	29 days,	range	
14–90  days	 post-HSCT)	 who	 were	 transplanted	 at	 a	 separate	
European	Institution	(Newcastle)	(Table 2).	As	conditioning	and	





(grade	 II	n =  22,	grade	 III	n =  2)	HSCT	patients	 transplanted	
between	2011	and	2014.	Clinical	presentation	included	skin	only	
5Crossland et al. Serum microRNA Expression in aGvHD




intensity	 conditioning	 (RIC)/myeloablative	 and	 MUD/sibling	










To	 further	 explore	 the	 biomarker	 potential	 of	 NanoString	
identified	microRNAs,	 selected	microRNAs	were	 also	 assessed	









age	 (p  =  0.98),	 or	 conditioning	 regimen	 (p  =  0.32)	 between	




MUD	 transplanted	 compared	 to	 those	 who	 were	 disease	 free,	
and	 there	was	also	a	higher	percentage	of	disease-free	patients	
who	were	 SIB	 transplanted	 compared	 to	 those	who	developed	
aGvHD	 (Table  2).	 However,	 when	 we	 adjusted	 for	 transplant	









microrna expression analysis at agvhD 
Diagnosis
NanoString	 results	 for	 one	 sample	 (patient	 number	 11,	 no	
aGvHD)	demonstrated	poor	data	normalization	and	thus	did	not	
pass	quality	 control	parameters.	 Subsequently,	 this	 sample	was	
excluded	from	further	analysis.









replication of Differential microrna 
expression at agvhD Diagnosis
To	verify	the	NanoString	data,	10	microRNAs	(miR-146a,	miR-
30b-5p,	 miR-374-5p,	 miR-20a,	 miR-15a,	 miR-181a,	 miR-18a,	
miR-19a,	 miR-19b,	 and	 miR-451a)	 were	 selected	 for	 further	
assessment	 in	 the	 diagnostic	 verification	 cohort	 (Table  2),	








lated	 in	 aGvHD,	 but	 not	 significantly	 (p =  0.06)	 (Figure  2B).	
There	 was	 no	 differential	 expression	 of	 miR-19a	 (p  =  0.50),	
miR-19b	(p = 0.95),	or	miR-451a	(p = 0.24)	(Figure 2B).	miR-







aGvHD	groups	 for	 transplant	 relationship,	 patient	 gender,	 and	
conditioning	(data	not	shown).	Although	some	of	the	tests	gave	
borderline-significant	 results,	 these	 were	 not	 consistent	 across	
cohorts,	so	it	is	unlikely	that	any	differences	in	the	microRNAs	
are	caused	by	clinical	factors.
correlations between micrornas at 
agvhD Diagnosis
Correlation	 analysis	 was	 performed	 between	 all	 candidate	
microRNAs	 assessed	 in	 the	 diagnostic	 verification	 cohort.	The	












association between micrornas 
Differentially expressed at agvhD 
Diagnosis and clinical Outcome
The	10	microRNAs	 that	were	 selected	 for	 analysis	 in	 the	diag-
nostic	 certification	 cohort	 were	 assessed	 for	 association	 with	
clinical	outcome	(OS	and	NRM).	High	expression	of	miR-19b	was	
FigUre 1 | nanostring-detected fold changes (Fcs) in microrna quantity between acute graft-versus- host disease (agvhD) vs. no agvhD 
patients. Eleven allohematopoietic stem cell transplantation patient serum samples (six aGvHD and five no aGvHD) were included in the final data set for 
microRNA expression assessment (n = 799) using the NanoString microRNA panel. (a) Volcano plot to show the relationship between FC and significance 
between the two groups. A FC comparison was made comparing aGvHD to no aGvHD. The horizontal dashed line indicates cutoff for significance p < 0.05 
(−log10 p > 1.3) and the vertical lines for FC ≥ 1.5/≤−1.5. (b) Heatmap showing hierarchical clustering of significantly differentially expressed microRNAs 
(p < 0.05, n = 61), based on normalized digital expression counts, in serum samples between patients with aGvHD vs. no aGvHD. Each column represents an 
individual patient. Relative expression changes are indicated by the color scale (red: high; blue: low). No aGvHD (none) cases are indicated in gray, while aGvHD 
cases (GvH) are indicated in black.
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significantly	associated	with	improved	OS	(p = 0.008)	(Figure 4A),	
but	 showed	no	 association	with	NRM	(p =  0.94)	 (Figure  4B).	
Elevated	expression	of	miR-20a	and	miR-30b-5p	was	significantly	
associated	with	improved	OS	(p = 0.016	and	p = 0.021,	respec-






In	 each	 case,	 the	 hazard	 ratio	 after	 adjusting	 for	 each	 variable	
did	not	differ	by	>10%,	 indicating	a	 true	 relationship	between	
expression	of	the	microRNA	and	NRM.
Differential microrna expression prior to 
agvhD Diagnosis
The	same	10	microRNAs	were	also	assessed	at	D14	post-HSCT,	
prior	 to	 disease	 onset,	 in	 an	 independent	 prognostic	 cohort	
(Table  2)	 to	 investigate	 their	 prognostic	 biomarker	 potential.	
miR-146a	 (p = 0.01),	miR-20a	 (p = 0.03),	miR-18a	 (p = 0.03),	
miR-19a	(p = 0.03),	miR-19b	(p = 0.01),	and	miR-451	(p = 0.01)	
were	 expressed	 at	 significantly	 higher	 levels	 in	 patients	 who	
went	on	to	develop	aGvHD	vs.	no	aGvHD	(Figure 5A).	In	ROC	








comparison of microrna expression 





aGvHD	 incidence.	 For	 both	 aGvHD	 and	 no	 aGvHD	 groups,	
expression	 levels	of	all	microRNAs	were	significantly	higher	 in	
the	 diagnostic	 cohort	 compared	 to	 the	D14	 prognostic	 cohort	




Pathway analysis of Differential 
micrornas at agvhD Diagnosis
Candidate	 microRNAs	 identified	 by	 NanoString	 analysis	 were	
assessed	 for	 identification	 of	 potential	 target	 genes.	 This	 is	 a	
complex	undertaking,	due	to	the	short	nature	of	seed	sequence	
FigUre 2 | Differential microrna expression in the diagnostic verification cohort. Expression of the candidate microRNAs was assessed by qRT-PCR at 
the onset of acute graft-versus- host disease (aGvHD) symptoms in serum samples of the diagnostic verification cohort (n = 42) and analyzed according to aGvHD 
incidence. (a) Verification of microRNAs that were downregulated at aGvHD onset according to NanoString analysis. (b) Verification of microRNAs that were 
upregulated at aGvHD onset according to NanoString analysis. Box plot whiskers represent minimum to maximum expression, and p Values were calculated using 
the independent two sample t-test.
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regions	 being	 complementary	 to	 multiple	 target	 genes.	 Thus,	
Ingenuity	Pathway	Analysis	was	used	to	identify	genes	and	clas-
sify	targets	into	networks	and	pathways.	Results	indicated	direct	






injury	 and	 abnormalities”	 pathway,	 including	miR-451a	 of	 the	
verification	microRNAs	(Figure	S2	in	Supplementary	Material).	
With	respect	to	diseases	and	functions,	5	of	61	microRNAs	were	
associated	 with	 inflammatory	 disease	 (miR-18a,	 miR-17-5p,	
miR-146a,	 miR-19b,	 and	 miR-92a),	 whereas	 19	 of	 61	 were	
















outcome,	 including	 albumin,	 IL-2	 receptor-α,	 tumor	 necrosis	














of	patients	or	a	 refined	signature	of	microRNAs	 limited	by	 the	
qRT-PCR	 technology	 used	 (13,	 17).	This	 study	 was	 based	 on	
NanoString	 technology,	which	 incorporates	 over	 700	 validated	
microRNA	targets	allowing	for	the	most	comprehensive	assess-
ment	of	circulating	microRNA	expression	in	a	HSCT	setting	to	
date.	 Results	 identified	 61	 microRNAs	 that	 were	 differentially	
expressed	between	patients	with	aGvHD	compared	to	those	who	
remained	disease	free.	Of	these,	10	were	selected	for	verification	




In	 the	 diagnostic	 verification	 cohort	 (n  =  42),	 miR-146a,	
miR-30b-5p,	 miR-374-5p,	 and	 miR-181	 were	 significantly	




untreated	controls,	 and	 transplantation	of	miR-146a	 -/-	T-cells	
resulted	in	increased	aGvHD	severity	and	reduced	survival	(31).	
In	 this	 study,	 miR-146a	 expression	 was	 significantly	 higher	 at	
FigUre 3 | association between serum micrornas and acute graft-versus- host disease (agvhD) at diagnosis by receiver operating characteristic 
analysis. Expression of candidate microRNAs was assessed by qRT-PCR at aGvHD onset in the verification cohort (n = 42) and analyzed according to aGvHD 
incidence. Receiver operating characteristic curves detailing area under the curve (A), p value, sensitivity, and specificity are shown.
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at	 a	 lower	 level	 following	 HSCT,	 it	 may	 be	 hypothesized	 that	






although	 it	has	been	 shown	 to	be	present	 in	 regulatory	T-cells	
(Tregs),	where	it	targets	eight	signaling	pathways	associated	with	
their	 function	 (39).	Expression	of	miR-374	has	been	 identified	
in	non-activated	natural	Tregs	(nTregs),	and	there	is	evidence	to	
suggest	that	nTregs	may	prevent	allograft	rejection	(40).	In	this	
context,	 it	may	 be	 surprising	 that	miR-374	 levels	 are	 lower	 at	
aGvHD	diagnosis;	however,	nTregs	comprise	just	5–10%	of	the	
circulating	 CD4+	 population,	 and	 pro-inflammatory	 cytokines	
released	during	the	acute	response	can	suppress	nTreg	function	
(41).	miR-181	acts	as	an	intrinsic	modulator	of	T-cell	sensitivity	







selected	 for	verification	as	 they	are	members	of	 the	miR-17-92	
cluster,	a	well	characterized	loci	that	plays	a	fundamental	role	in	
T-cell	differentiation,	survival,	and	function	as	well	as	autoimmune	




or	 miR-19b	 inhibits	 alloreactive	 T-cell	 expansion	 and	 IFN-γ	
FigUre 4 | association between serum micrornas and acute graft-versus- host disease (agvhD) clinical outcome. Expression of candidate microRNAs 
was assessed by qRT-PCR at aGvHD onset in the verification cohort (n = 42) and analyzed according to outcome. (a) Overall survival according to microRNA 
expression in relation to follow-up from time of transplant to event. p Values were calculated using the log-rank test. (b) Non-relapse mortality (NRM) according to 
microRNA expression in relation to time from transplant to event. Dichotomized microRNA expression in relation to relapse and NRM is depicted by dotted and solid 
black and gray lines, respectively. p Values were calculated according to the Fine and Gray competing risk method.
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developing	 GvHD	 following	 HSCT	 and	 the	 use	 of	 miR-155	







serum,	which	 also	 correlated	with	disease	 severity;	 however,	
this	study	was	restricted	to	a	Han	Chinese	population	(n = 64)	
(14).	Collectively,	the	findings	may	highlight	the	heterogene-
ous	 nature	 of	 microRNA	 expression	 that	 is	 both	 tissue	 and	
condition	 specific.	Thus,	 despite	 promising	 results	 in	 tissue	
(49),	 this	may	not	be	reflective	of	miR-155	expression	 in	 the	
circulation.
A	small	study	by	Sang	et al.	additionally	reported	upregula-
tion	 of	 miR-92b	 in	 serum	 samples	 at	 aGvHD	 onset,	 while	
miR-150	 and	 miR-181	 were	 significantly	 downregulated	 (15).	





aGvHD	compared	 to	patients	who	 remained	aGvHD	free	 (FC	
−2.26,	p = 0.046).	miR-181a	has	been	shown	to	enhance	CD4+	
T  lymphocytes	 toward	Th2	and	Treg	differentiation,	by	 target-
ing	 IFN-γ,	 and	expression	 levels	 correlate	with	 IFN-γ	 protein,	
but	 not	 mRNA	 expression	 (15).	 Further	 in-depth	 analysis	 of	
FigUre 5 | continued
10
Crossland et al. Serum microRNA Expression in aGvHD
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 308
FigUre 6 | Differential microrna expression between prognostic and diagnostic samples. Expression of the candidate microRNAs was compared 
between the diagnostic cohort (n = 42) and the day 14 prognostic cohort (n = 47) and analyzed according to acute graft-versus-host disease incidence. Box plot 
whiskers represent minimum to maximum expression, and p values were calculated between groups using the independent two sample t-test.
FigUre 5 | continued 
Differential microrna expression in the prognostic cohort. Expression of the candidate microRNAs was assessed by qRT-PCR at day 14 posthematopoietic 
stem cell transplantation in the validation prognostic cohort (n = 47) and analyzed according to acute graft-versus-host disease (aGvHD) incidence. (a) microRNA 
expression according to aGvHD vs. no GvHD. Box plot whiskers represent minimum to maximum expression, and p values were calculated using the independent 
two sample t-test. (b) Receiver operating characteristic curves for incidence of aGvHD to determine prognostic ability of microRNA expression. The area under the 
curve (A), p value, sensitivity, and specificity are shown.
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199-3p,	miR-93*,	 and	miR-377)	 that	 significantly	predicted	 for	
aGvHD	at	6 weeks	post-HSCT,	prior	to	the	onset	of	symptoms.	
Furthermore,	the	model	was	associated	with	disease	severity	and	
poor	OS	 (13).	This	 study	 highlighted	 the	 potential	 of	 biofluid	
microRNAs	 as	 independent	markers	 for	 prediction,	 prognosis,	
and	diagnosis	of	GvHD.	Gimondi	et al.	also	profiled	circulating	
microRNA	 expression	 using	 a	 qRT-PCR-based	 platform	 (17).	
They	assessed	samples	collected	28 days	post-HSCT	and	detected	
113	 microRNAs,	 of	 which	 27	 could	 collectively	 discriminate	
between	 aGvHD	 vs.	 no	 aGvHD.	miR-194	 and	miR-518f	 were	
significantly	upregulated	in	patients	who	later	developed	aGvHD,	
and	 pathway	 prediction	 analysis	 identified	 these	 microRNAs	
to	 target	 critical	 pathways	 implicated	 in	 aGvHD	 pathogen-
esis	 (17).	 However,	 there	 was	 no	 verification	 cohort	 included	




in	 this	 study,	 this	did	not	 reach	significance.	When	comparing	
the	27	unique	microRNAs	formerly	identified	by	Gimondi	et al.,	
7	 (miR-374b/20a/185/191/30b)	 were	 also	 significantly	 associ-
ated	with	aGvHD	in	this	study,	while	no	statistically	significant	
overlap	was	 identified	 for	 the	 remaining	microRNAs.	The	 lack	
of	 reproducibility	 between	microRNA	profiling	 studies	 to	 date	
may	not	be	 surprising,	due	 to	 the	high	degree	of	 variability	 in	
factors	when	designing	and	performing	these	experiments,	which	
may	 be	 attributed	 to	 clinical	 (patient	 characteristics,	 sampling	
time	points,	and	type	of	body	fluid	analyzed),	technical	(sample	
preparation,	 microRNA	 profiling	 platform,	 and	 spectrum	 of	




treatment	prophylaxis,	 and	conditioning	 regimen	 to	 reflect	 the	
diverse	population	of	HSCT	patients	who	develop	aGvHD.	Xiao	
et al.	used	a	similar	approach	(13);	however,	the	patients	in	the	
study	 by	Gimondi	 et  al.	 were	 restricted	 to	 lymphoma	 patients	
in	 complete	 remission	 undergoing	 RIC	 (17).	 In	 addition,	 dif-
ferent	 time	points	of	 sampling	were	used	 in	 these	 studies,	 and	
Xiao	 et  al.	 investigated	 plasma	 taken	 6  weeks	 posttransplant	
(10)	and	Gimondi	et al.	focused	on	day	+28	posttransplant	(17).	





less	 likely	 to	 be	 affected	 by	 hemolysis	 than	 plasma,	 where	 the	
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as	well	 as	 selective	 loss	 of	 small	 RNA	molecules	with	 low	GC	
content	(51).	The	choice	of	microRNA	detection	platform	is	par-
ticularly	important	when	distinguishing	small	molecules	at	low	
abundance	and	with	high	 sequence	homology	 (52).	Xiao	 et  al.	
based	their	assessment	on	Sybr-green	dye,	which	lacks	specificity	
in	 comparison	 to	 the	 TaqMan	 low-density	 array	 employed	 by	
Gimondi	et al.	(17).	However,	qRT-PCR	is	still	reliant	on	reverse	
transcription	of	RNA	to	cDNA,	which	can	introduce	bias.	This	
study	 relied	on	NanoString	profiling,	which	 is	 based	on	direct	
hybridization	of	reporter	molecules	 to	RNA,	and	thus	removes	
the	need	for	reverse	transcription.	The	analysis	is	based	on	a	direct	

















biological	 variation	 (56).	 While	 Gimondi	 et  al.	 calculated	












clinical	 centers.	This	 may	 be	 achieved	 through	 collaboration	
between	 research	 groups,	 focusing	 on	 standardization	 of	 the	
samples,	 protocols,	 and	 technologies	 used,	 which	 will	 greatly	
improve	 the	 reproducibility	 of	 findings	 allowing	 for	 extended	
validation	of	microRNAs	of	 interest.	The	ultimate	aim	will	be	
to	 diagnose	 GvHD	 and	 predict	 outcome	 before	 the	 onset	 of	
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